First Patient Dosed in Ph 3 ALPACCA Trial of Firmonertinib in 1L EGFR PACC Mutant NSCLC December 30, 2025
Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL December 30, 2025
First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland Announced December 30, 2025
Update Provided on Pivotal Ph 3 REGAL Trial of Galinpepimut-S (GPS) in AML; no outcome analyses performed December 30, 2025
First pancreatic cancer patient in global Ph 3 registrational trial, MAPKeeper 301, to be dosed in mid-2026 December 30, 2025
First Patient Dosed in Ph 1/2 Trial of CRN09682 for the Treatment of NETs and Other Somatostatin Receptor 2-Expressing Tumors December 9, 2025
DESTINY-Ovarian01 Ph 3 Trial of ENHERTU® Initiated as 1L Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer December 9, 2025
Positive Recommendation from IDMC to Continue Pivotal Ph 3 ARTEMIA Trial Evaluating Tedopi® in NSCLC November 24, 2025
Update provided on Ph 1/2a AERIAL trial of LEU011 in patients with R/R solid tumours November 18, 2025
First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC November 18, 2025
First Patient Dosed in Randomized Dose Optimization Cohort of Ph 2 Study of Muzastotug + KEYTRUDA in MSS-CRC November 10, 2025
